Peripheral Arterial Disease Market Outlook 2024: Exclusive Report By The Business Research Company | Cardinal Health Inc., Johnson and Johnson Limited, Abbott Laboratories, Medtronic PLC

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Peripheral Arterial Disease Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The peripheral arterial disease market size has grown strongly in recent years. It will grow from $4 billion in 2023 to $4.36 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to innovative medical devices, gene therapy and regenerative medicine, pharmacogenomics, digital health and remote monitoring.

The peripheral arterial disease market size is expected to see strong growth in the next few years. It will grow to $6.05 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to interdisciplinary care teams, minimally invasive interventions, lifestyle and exercise prescriptions. Major trends in the forecast period include vascular tele-rehabilitation, multimodal pain management, wound care advances, public health campaigns.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12999&type=smp

Market Segmentation:
The main treatment types for peripheral arterial disease are devices, catheters, drugs and others. Devices for peripheral artery disease (PAD) refer to medical devices that are used for the diagnosis, treatment and management of the condition. The various routes of administration include oral, parenteral and others. These are used by various end-users such as hospitals, specialty clinics and others.

Major Driver - Cardiac Disease Prevalence Fuels Growth In The Peripheral Arterial Disease Market
The rising prevalence of cardiac diseases is driving the growth of the peripheral arterial disease market going forward. Cardiac disease is a typical heart disease that impacts the main blood vessels supplying the heart muscle. Peripheral arterial disease treatment helps cardiac patients with improved blood flow, cardiovascular risk reduction, symptom relief and enhanced quality of life. For instance, in June 2023, according to the Center for Disease Control and Prevention, a US-based government agency, the number of deaths due to cardiovascular diseases reached 695,547 in 2021. Additionally, in April 2022, according to the American College of Cardiology, a US-based non-profit medical association, the risk factors for ischemic heart disease are predicted to increase by 30.7% to 29 million by 2025. Therefore, the rising prevalence of cardiac diseases drives the peripheral arterial disease market.

Competitive Landscape:
Major players in the peripheral arterial disease market are Cardinal Health Inc., Johnson and Johnson Limited, Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips N.V., Boston Scientific Corporation, B. Braun SE, Terumo Corp., Cook Medical LLC, Penumbra Inc., Shockwave Medical Inc., AngioDynamics Inc., Cardiovascular Systems Inc., ACIST Medical Systems Inc., SurModics Inc., Endologix Inc., BioVentrix Inc., QT Vascular Ltd., Avinger Inc., Mercator MedSystems Inc., VentureMed Group Ltd., Eximo Medical Ltd., LimFlow SA, Contego Medical LLC.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/peripheral-arterial-disease-global-market-report

Top Trend - Innovative Drug Development Initiatives Driving Advancements In The Peripheral Arterial Disease Market
Major companies operating in the peripheral arterial disease market are focused on developing innovative drugs and solutions to sustain their position in the market. Drug development can lead to the development of more effective treatments for PAD, reducing the risk of complications and improving patient outcomes. For instance, in August 2021, The Janssen Pharmaceutical Companies, a Belgium-based pharmaceutical company, received approval for an expanded peripheral artery disease (PAD) indication for the XARELTO (rivaroxaban) dose by the Food and Drug Administration (FDA), a US-based government agency. XARELTO is the first and only therapy for both coronary artery disease (CAD) and PAD, including PAD patients post-LER. This is also recommended for patients with acute limb ischemia and amputation, ischemic stroke and myocardial infarction.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Peripheral Arterial Disease Market Characteristics
3. Peripheral Arterial Disease Market Trends And Strategies
4. Peripheral Arterial Disease Market - Macro Economic Scenario
5. Peripheral Arterial Disease Market Size And Growth
…..
27. Peripheral Arterial Disease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.